619 related articles for article (PubMed ID: 28214886)
1. Adenovirus Vector Harboring the HBcAg and Tripeptidyl Peptidase II Genes Induces Potent Cellular Immune Responses In Vivo.
Tan Q; Ma S; Hu J; Chen X; Yu Y; Tang Z; Zang G
Cell Physiol Biochem; 2017; 41(2):423-438. PubMed ID: 28214886
[TBL] [Abstract][Full Text] [Related]
2. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances HBV-specific humoral and CTL immune responses in vivo.
Song L; Zhuo M; Tang Y; Chen X; Tang Z; Zang G
Int Immunopharmacol; 2014 Nov; 23(1):1-7. PubMed ID: 25135878
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the role of tripeptidyl peptidase II in MHC class I antigen presentation in vivo.
Kawahara M; York IA; Hearn A; Farfan D; Rock KL
J Immunol; 2009 Nov; 183(10):6069-77. PubMed ID: 19841172
[TBL] [Abstract][Full Text] [Related]
5. An Engineered DC-Targeting Lentivector Induces Robust T Cell Responses and Inhibits HBV Replication in HBV Transgenic Mice via Upregulating T Cell Autophagy.
Ma S; Chen X; Tan Q; Dai S; Li D; Wu S; Yu Y; Zang G; Tang Z
Cell Physiol Biochem; 2018; 48(3):1041-1059. PubMed ID: 30041239
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus vector encoding TPPII ignites HBV-specific CTL response by activating autophagy in CD8+ T cell.
Tan Q; Chen J; Gao G; Yizhang ; Chen X; Yu Y; Zang G; Tang Z
J Viral Hepat; 2022 Mar; 29(3):178-188. PubMed ID: 34902200
[TBL] [Abstract][Full Text] [Related]
7. Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo.
Chen X; Tang Y; Zhang Y; Zhuo M; Tang Z; Yu Y; Zang G
Lab Invest; 2014 May; 94(5):478-90. PubMed ID: 24614195
[TBL] [Abstract][Full Text] [Related]
8. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
Martin P; Dubois C; Jacquier E; Dion S; Mancini-Bourgine M; Godon O; Kratzer R; Lelu-Santolaria K; Evlachev A; Meritet JF; Schlesinger Y; Villeval D; Strub JM; Van Dorsselaer A; Marchand JB; Geist M; Brandely R; Findeli A; Boukhebza H; Menguy T; Silvestre N; Michel ML; Inchauspé G
Gut; 2015 Dec; 64(12):1961-71. PubMed ID: 25429051
[TBL] [Abstract][Full Text] [Related]
9. Delivery of Tapasin-modified CTL epitope peptide via cytoplasmic transduction peptide induces CTLs by JAK/STAT signaling pathway in vivo.
Wu S; Chen X; Tang Y; Zhang Y; Li D; Chen J; Wang J; Tang Z; Zang G; Yu Y
Acta Biochim Biophys Sin (Shanghai); 2018 Feb; 50(2):181-190. PubMed ID: 29340620
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances the hepatitis B virus-specific cytotoxic T-lymphocyte immune response and inhibits hepatitis B virus replication in transgenic mice.
Zhuo M; Song L; Tang Y; Dai S; Chen X; Yu Y; Zang G; Tang Z
Mol Med Rep; 2015 Sep; 12(3):3591-3598. PubMed ID: 26004262
[TBL] [Abstract][Full Text] [Related]
11. Fusion protein of tapasin and hepatitis B core antigen 18‑27 enhances T helper cell type 1/2 cytokine ratio and antiviral immunity by inhibiting suppressors of cytokine signaling family members 1/3 in hepatitis B virus transgenic mice.
Tang Y; Chen X; Zhang Y; Tang Z; Zhuo M; Li D; Wang P; Zang G; Yu Y
Mol Med Rep; 2014 Apr; 9(4):1171-8. PubMed ID: 24535102
[TBL] [Abstract][Full Text] [Related]
12. The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice.
Chen X; Lai J; Pan Q; Tang Z; Yu Y; Zang G
Vaccine; 2010 May; 28(23):3913-9. PubMed ID: 20394723
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell-based vaccination with lentiviral vectors encoding ubiquitinated hepatitis B core antigen enhances hepatitis B virus-specific immune responses in vivo.
Dai S; Zhuo M; Song L; Chen X; Yu Y; Tang Z; Zang G
Acta Biochim Biophys Sin (Shanghai); 2015 Nov; 47(11):870-9. PubMed ID: 26373843
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
Zhou C; Peng G; Jin X; Tang J; Chen Z
Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
[TBL] [Abstract][Full Text] [Related]
17. [HBcAg-specific CTL response induced by PTD-HBcAg fusion protein to inhibit HBV replication in vitro].
Chen XH; Pan QC; Yu YS; Tang ZH; Zang GQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Apr; 25(4):289-92. PubMed ID: 19351491
[TBL] [Abstract][Full Text] [Related]
18. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
[TBL] [Abstract][Full Text] [Related]
19. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of CTLs induced by DCs loaded with ubiquitinated hepatitis B virus core antigen.
Chen JH; Yu YS; Chen XH; Liu HH; Zang GQ; Tang ZH
World J Gastroenterol; 2012 Mar; 18(12):1319-27. PubMed ID: 22493545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
